Fundraising Fox

Krishnan Nandabalan

InvestorFounder

CEO, Founder, & President, InveniAI at AIF · Chief Executive Officer, President and Chairman at Invea Therapeutics, Inc.

Branford, Connecticut, United States

FoundedInvea Therapeutics, Inc.

About

Krishnan Nandabalan is President, Chairman, and CEO of AlphaMeld Corporation and President and CEO of InveniAI Corporation, a technology spinout focused on applying big data analytics and machine learning to drug and target discovery. With over two decades in pharmaceutical and biotechnology R&D, operations, and business development, he has completed licensing and M&A transactions with major industry players and previously served as VP of Corporate Development at Genaissance Pharmaceuticals and Group Leader of Functional Genomics at CuraGen Corporation. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, completed a postdoctoral fellowship at Yale University, and has 12 issued patents and publications in peer-reviewed journals including Cell and Science.

Chief Executive Officer, President and Chairman at Invea Therapeutics, Inc.

Intro paths

In turn, Krishnan can intro founders to Invea Therapeutics, Inc.'s investors below.

Invea Therapeutics, Inc.'s investors · 1

Experience

  1. AlphaMeld CorporationPresident, Chairman, and CEO of AlphaMeld Corporationcurrent2024 — presentGuilford, Connecticut, United States
  2. AlphaMeld CorporationBoard Membercurrent2017 — presentGuilford, Connecticut, United States
  3. Invea TherapeuticsFounder, Chairman, President, CEOcurrent2021 — presentGuilford, Connecticut, United States
  4. InveniAI LLCPresident, CEO, and Foundercurrent2017 — presentGuilford, Connecticut, United States
  5. BioXcel Therapeutics, Inc.Board Member2017 — 2023New Haven, Connecticut, United States
  6. BioXcel CorporationPresident and Co-Founder2005 — 2023Guilford, Connecticut, United States
  7. BioXcel CorporationBoard Member2005 — 2023Guilford, Connecticut, United States
  8. Genaissance PharmaceuticalsVP Corporate Development1998 — 2005New Haven, CT
  9. CuraGen CorporationGroup Leader, Functional Genomics1995 — 1998

Skills & more

Life Sciences12Biotechnology19Molecular Biology14Drug Discovery10Biochemistry9Pharmaceutical Industry9Genomics9Technology Transfer9Commercialization4Genetics5Immunology4Cell Biology3
+12 moreBiopharmaceuticalsBioinformaticsDrug DevelopmentBiomarkersLifesciencesR&DStart-upsEntrepreneurshipCross-functional Team LeadershipInnovationNeuroscienceOncology

From Krishnan's professional profile.

Colleagues at AIF

Frequently asked questions

Who is Krishnan Nandabalan?
Krishnan Nandabalan is President, Chairman, and CEO of AlphaMeld Corporation and President and CEO of InveniAI Corporation, a technology spinout focused on applying big data analytics and machine learning to drug and target discovery. With over two decades in pharmaceutical and biotechnology R&D, operations, and business development, he has completed licensing and M&A transactions with major industry players and previously served as VP of Corporate Development at Genaissance Pharmaceuticals and Group Leader of Functional Genomics at CuraGen Corporation. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, completed a postdoctoral fellowship at Yale University, and has 12 issued patents and publications in peer-reviewed journals including Cell and Science.
Where does Krishnan Nandabalan work?
Krishnan Nandabalan is Chief Executive Officer, President and Chairman of Invea Therapeutics, Inc. and CEO, Founder, & President, InveniAI at AIF.
What companies did Krishnan Nandabalan found?
Krishnan Nandabalan founded Invea Therapeutics, Inc..
Where did Krishnan Nandabalan go to school?
Krishnan Nandabalan studied at Yale University (Post-Doctoral Fellow, Yeast Genetics); University of Kentucky (Post Doctoral Fellow); Indian Institute of Science (IISc) (Ph.D., Biochemistry and Molecular Biology).

Founder mafias

Same school

Shared employers